• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    iShares U.S. Pharmaceutical ETF (NY:IHE)

    84.78 +0.80 (+0.95%)
    Streaming Delayed Price Updated: 11:10 AM EDT, Mar 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about iShares U.S. Pharmaceutical ETF

    < Previous 1 2 3 Next >
    News headline image
    FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗
    The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary. 
    Via Stocktwits
    News headline image
    TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗
    The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint. 
    Via Stocktwits
    Topics Workforce
    News headline image
    FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
    Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments. 
    Via Stocktwits
    Topics ETFs Government
    News headline image
    Why Did IINN Stock Surge 28% In Pre-Market Today? ↗
    The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members. 
    Via Stocktwits
    KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗
    Via Stocktwits
    Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
    Via Stocktwits
    White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
    Via Stocktwits
    News headline image
    HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
    The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
    Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data. 
    Via Stocktwits
    News headline image
    US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
    The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
    Via Stocktwits
    Topics World Trade
    News headline image
    Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗
    A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize. 
    Via Benzinga
    Topics ETFs
    News headline image
    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
    Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
    Via Benzinga
    News headline image
    Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
    As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
    Via Benzinga
    Topics ETFs
    News headline image
    Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
    The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
    Via Benzinga
    Topics ETFs
    News headline image
    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
    President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
    Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
    Via Benzinga
    News headline image
    Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
    Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
    Via Benzinga
    News headline image
    Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
    Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
    Via Benzinga
    News headline image
    Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗
    Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
    Via Benzinga
    Topics Artificial Intelligence ETFs
    News headline image
    Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
    Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗
    FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television. 
    Via Stocktwits
    Topics Government
    News headline image
    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
    Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗
    A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
    Via Benzinga
    News headline image
    FDA Aims To Reduce Drug Application Review Time With New Voucher Program ↗
    The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final... 
    Via Stocktwits
    News headline image
    Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading ↗
    A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
    Via Benzinga
    News headline image
    Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗
    Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket. 
    Via Benzinga
    Topics Government
    News headline image
    Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗
    Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
    Via Benzinga
    Topics Government
    News headline image
    Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
    Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
    Via Benzinga
    Topics ETFs Government
    News headline image
    Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗
    Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
    Via Stocktwits
    Topics Government Intellectual Property Lawsuit
    News headline image
    Trump Administration Considers Lowering US Drug Prices To International Levels: Report ↗
    The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
    Via Benzinga
    Topics Government
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.